Immuno-fibrotic drivers of impaired lung function in post-COVID-19 syndrome

Hyung J. Chun, MD[1*], Elias Coutavas, PhD[2], Alexander Pine, MD[3], Alfred I. Lee, MD, PhD[3], Vanessa Yu, BA[1], Marcus Shallow[1], Coral X. Giovacchini, MD[2], Anne Mathews, MD[2], Brian Stephenson, DO[2], Loretta G. Que, MD[2], Patty J. Lee, MD[2], Bryan D. Kraft, MD[2*]

[1]Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, 06510.
[2]Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC, 27710.
[3]Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, 06510.

*Correspondence to: Hyung J. Chun, MD (hyung.chun@yale.edu) or Bryan D. Kraft, MD (bryan.kraft@duke.edu)

Author contributions: H.J.C. and B.D.K. wrote the manuscript that was approved by all authors. All authors participated in data collection, analysis, and/or interpretation. The overall study design was conceived by Y.J.C., B.D.K., L.G.Q., A.I.L., and P.J.L.

Funding: The study was funded in part by the NHLBI (K08HL130557 to BDK and R01HL142818 to HJC), the DeLuca Foundation Award (AP), a donation from Jack Levin to the Benign Hematology Program at Yale, and Divisional/Departmental funds from Duke University.

Summary: COVID-19 “long-haulers” display impaired lung function and a lung recovery host response that is proportionate to degree of acute lung injury. Novel biomarkers of inflammation, fibrosis, and alveolar repair may reflect underlying biological drivers of post-COVID-19 syndrome.

Running title: Drivers of impaired lung function after COVID-19

ABSTRACT

Subjects recovering from COVID-19 frequently experience persistent respiratory ailments; however, little is known about the underlying biology that directs lung recovery and its relation to COVID-19 severity. We performed a cohort study of subjects with lingering symptoms after COVID-19, collecting clinical data, pulmonary function tests, and plasma for multiplex biomarker profiling. Sixty-one subjects were enrolled across two academic medical centers at a median of 9 weeks post-COVID-19: n=13 (21%) mild/non-hospitalized, n=30 (49%) hospitalized/non-critical, and n=18 (30%) hospitalized/ICU. Dyspnea (69%) and cough (58%) were common. Pulmonary function at follow-up declined as acute COVID-19 severity increased ($P<0.05$), but did not correlate with symptoms. Partial least-squares discriminant analysis of biomarkers clustered subjects by COVID-19 severity. Lipocalin 2 (LCN2), matrix metalloproteinase-7 (MMP-7), and hepatocyte growth factor (HGF) were significantly higher in ICU subjects ($P<0.05$), and inversely correlated with pulmonary function ($P<0.05$). These host response profiles reflecting neutrophil activation, fibrosis signaling, and alveolar repair, respectively, may be novel therapeutic or prognostic targets in post-COVID-19 syndrome.

INTRODUCTION

As the number of patients who recover from acute coronavirus disease 19 (COVID-19) rises, it is increasingly apparent that a substantial subset displays persistent subjective and objective respiratory ailments. Patients report a high prevalence of lingering respiratory symptoms such as fatigue and dyspnea (1-4), and spirometry and diffusion capacity testing show impaired pulmonary function (3). However, little is known about the biological drivers of long-term respiratory disease after COVID-19, and how acute COVID illness severity impacts the emerging COVID-19 “long-hauler syndrome”. To better understand the relationship between subjective and objective respiratory abnormalities and underlying biological drivers, we measured symptom burden, pulmonary function tests, and plasma biomarkers in subjects that have recovered from COVID-19 infection.

METHODS

Subject Enrollment

The studies were approved by the institutional review boards of Yale University (#2000027792 and #1401013259) and Duke University (Pro00105518 and Pro00106151). Subjects with persistent symptoms after recovering from COVID-19 infection were recruited to a post-COVID-19 clinic for further evaluation. Written informed consent was provided by all subjects prior to study activities.

Data Collection

All subjects completed symptom questionnaires (presence or absence of the following: fatigue, fever, headache, dyspnea, cough, chest pain, nausea, diarrhea, anosmia, dysgeusia, sore throat, nasal congestion, red eyes, and vision loss), physical examinations, and pulmonary function testing (spirometry and diffusion capacity) at the time of their follow-up visits. Symptom scores were calculated by the sum of the number of symptoms reported. Severity of COVID-19 infection was defined by need for intensive care unit (ICU) hospital care, non-ICU hospital care (non-ICU), or non-hospitalized home recuperation (home). Whole blood was collected by venipuncture, centrifuged, separated into plasma, and stored at -80°C until use.

Plasma biomarker profiling

Multiplex profiling of plasma was performed on a subset of subjects (n=22) by Eve Technologies (Calgary, Alberta, Canada) using the following assays: Human Cytokine 71-Plex, Human Complement Panel 1, Human Angiogenesis 17-Plex, Human MMP 9-Plex and TIMP 4- Plex, and Human Adipokine 5-Plex. A complete list of biomarkers profiled is provided in the **Supplemental Table**.

Statistical Analysis

Grouped data are expressed as median (interquartile range) unless specified otherwise. Differences between groups were analyzed by Kruskal-Wallis test with Benjamini-Hochberg post-hoc test to control for false discovery rate or one-way ANOVA with Fisher's LSD post-hoc test (Graphpad Prism, San Diego, CA). Simple linear regression were performed by Prism. Partial least-squares discriminant analysis (PLS-DA) was performed using SIMCA v15 (Umetrics, Umeå, Sweden). The random-forest feature selection (Boruta algorithm) was performed using the Boruta package in R software. All P-values are two-tailed. $P<0.05$ was accepted as statistically significant.

RESULTS AND DISCUSSION

We enrolled 61 subjects into the post-COVID-19 clinics. Subject demographics for each group are shown in the **Table**. Median (IQR) age was 53 (43-62) years and sex distribution was equitable: 56% males and 44% females. Median (IQR) time from onset of COVID-19 infection to post-COVID follow up was 9 (6-11) weeks. Thirteen subjects (21%) recovered at home ("home" group), 30 subjects (48%) were hospitalized but did not require ICU ("non-ICU" group) and nineteen subjects (31%) were hospitalized and required ICU level care ("ICU" group). Nine of the subjects admitted to the ICU required intubation and mechanical ventilation.

Fifty-three subjects (85%) reported lingering symptoms of COVID-19, the most common being dyspnea (69%), cough (58%), fever (47%), fatigue (29%), chest pain (26%), and headache (23%) (**Figure 1A**). There were no significant differences in symptom burden between the home, non-ICU, and ICU groups (P=NS, **Figure 1B**). Pulmonary function testing was performed on 59 subjects. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and diffusing capacity for carbon monoxide (DLCO) decreased as severity of COVID-19 increased (**Figure 2A**). There was no relationship between pulmonary function and presence of persistent respiratory symptoms, measured by the sum of the scores for fatigue, dyspnea, and cough (**Figure 2B**). Others have also found these symptoms are common in

patients recovering from acute COVID-19 infection (1-4), and do not associate with COVID-19 severity (3). Impaired pulmonary function was also reported by Townsend et al (1), and similar to our findings, correlated well with prior COVID-19 severity. Together these data highlight the discordance of subjective and objective respiratory abnormalities after COVID-19 infection and indicate that subjective symptoms alone cannot discern degree of post-COVID-19 lung function impairment.

To identify potential biological factors that associate with impaired pulmonary function after COVID-19 infection, we measured levels of circulating inflammatory, metabolic, angiogenic, and fibrotic markers in plasma from a subset of 22 subjects (home group n=7, non-ICU group n=5, ICU group n=10) and performed partial least-squares discriminant analysis (PLS-DA) (**Figure 3**). The score plot (**Figure 3A**) shows that subjects largely cluster in distinct quadrants based on how severe their COVID-19 illness was, even ~9 weeks after infection. In fact, the clustering shows a counter-clockwise rotation around the origin as severity of viral infection increases from home to non-ICU to ICU-level of care. The loadings plot (**Figure 3B**) shows the associations between the clusters of subjects and the measured plasma biomarkers (**Supplemental Table**). The top right quadrant shows the biomarkers that directly correlate with critical COVID-19 illness requiring ICU admission. Several of the most impactful biomarkers (i.e. furthest from the point of origin) that associate with ICU level of care are LCN2 (lipocalin-2), MMP-7 (matrix metalloproteinase-7), and HGF (hepatocyte growth factor). Plasma levels of all three factors were significantly higher in the ICU group compared to the home group (**Figure 4A**). These factors were also previously found to be elevated during acute COVID-19 critical illness (5), suggesting: 1) they can be followed longitudinally as markers of illness severity; and 2) the host response during acute COVID-19 may overlap with post-COVID-19 syndrome.

To further determine if specific circulating factors are associated with persistently impaired pulmonary function, we used random-forest feature selection (6) to identify which factors best explain the variability seen in FVC and DLCO (**Supplemental Figures 1-2**). This

analysis identified MMP-7 as the marker that was most significantly associated with FVC and DLCO. LCN2, HGF, and leptin, among others were also significantly associated with FVC, DLCO, or both. Leptin is a hormone secreted by adipocytes in proportion to obesity, a risk factor for severe acute COVID-19 (7), and may contributes to immune dysregulation during acute COVID-19 (8, 9). In our patient cohort, leptin did not differ by acute COVID-19 severity, but was strongly inversely correlated with post-COVID-19 FVC and also directly correlated with body mass index (**Supplemental Figure 3**). As it relates to post-COVID-19 syndrome, it is not clear if leptin levels simply reflect obesity (which can reduce FVC alone), represent ongoing immune dysregulation, or both.

Comparison of LCN2, MMP-7, and HGF with pulmonary function using simple linear regression identified a highly significant, inverse correlation with FVC and DLCO (**Figure 4B**). LCN2 is a component of neutrophil secondary granules that was found to strongly associate with acute COVID-19 critical illness and mortality (5, 10-12); however, the role in post-COVID-19 recovery has not been previously described. That higher levels of LCN-2 are found at 9 weeks after severe COVID-19 illness compared with non-severe cases suggests these patients may have ongoing neutrophil activation that could be amenable to targeted therapy.

MMP-7 is a protease that breaks down extracellular matrix deposited in the lung after injury. The role of MMP-7 in COVID-19 has not been reported. However, previous studies of non-COVID-19 acute lung injury have shown higher circulating levels of MMPs (13) that associate with worse disease severity and clinical outcomes (14). MMP-7 is also a validated biomarker for idiopathic pulmonary fibrosis severity that correlates with pulmonary function (15), and our findings suggest MMP-7 may be a novel biomarker of COVID-19 ARDS recovery.

HGF is a growth factor secreted by alveolar fibroblasts shown to be elevated in bronchoalveolar lavage fluid of patients with ARDS (16) and in plasma of patients with acute COVID-19 illness (17); however, the plasma levels after COVID-19 recovery have not been previously reported. In vivo and in vitro studies indicate HGF promotes alveolar epithelial and

endothelial repair after acute lung injury (18, 19) via induction of counter inflammatory and anti-oxidant gene expression (20-22). Our findings suggest high HGF levels at 9 weeks post-COVID-19 could indicate ongoing alveolar repair proportionate to the degree of acute lung injury; however, further studies are needed to determine the impact of HGF on COVID-19 recovery.

Our study has several limitations. First, we only recruited subjects that had ongoing symptoms after COVID-19 infection, therefore we cannot report the true prevalence of symptoms or pulmonary function derangements in subjects with asymptomatic infection or in subjects with symptom resolution after COVID-19 infection. Second, our plasma biomarker profiles represent a single time point for each subject, and therefore we cannot draw conclusions about trajectory or changes over time. Third, we cannot establish mechanism in this human cohort study; however, our findings are associational and lay the foundations to drive further work in this area.

In conclusion, persistent respiratory symptoms and impaired lung function are common after acute COVID-19 illness, but subjective symptoms alone do not predict lung injury. Partial least-squares discriminant analysis reliably identifies and separates subjects by COVID-19 illness severity based on their plasma biomarker profiles, even 9 weeks after recovery. Circulating factors associated with acute neutrophil activation, fibrosis signaling, and alveolar epithelial repair remain elevated in survivors of acute COVID-19 infection and strongly associate with impaired pulmonary function. Our study provides novel insights into divergent host responses of lung repair after COVID-19 pneumonia and suggest that immunologic and fibrotic drivers of disease severity in the acute COVID-19 illness may regulate the trajectory of recovery in the post-COVID-19 phase. These markers may represent novel therapeutic targets and may identify COVID-19 survivors at increased risk for chronic parenchymal lung disease, and will require validation in a larger study.

Table: Subject Demographics

	Post-COVID-19 Clinic N=61
Age (years), median (IQR)	53 (43-65)
Sex, N (%)	
Female	27 (44%)
Male	34 (56%)
Ethnicity, N (%)	
Hispanic/Latino	10 (16%)
Not Hispanic/Latino	47 (77%)
Unknown	4 (7%)
Race, N (%)	
African American	13 (21%)
American Indian or Alaskan Native	2 (3%)
Asian	2 (3%)
Caucasian	39 (64%)
Two or more races	1 (2%)
Unknown	4 (7%)
Body mass index, median (IQR)	30 (26-37)
COVID-19 Severity, N (%)	
Home	13 (21%)
Hospitalized, non-ICU	30 (49%)
Hospitalized, ICU	18 (30%)
Intubated, N (%)	8 (13%)
Weeks since COVID-19, median (IQR)	9 (6-10)

Abbreviations: COVID-19, coronavirus disease 2019; ICU, intensive care unit; IQR, interquartile range; N, number.

FIGURE LEGENDS

Figure 1: Post-COVID-19 symptom burden. A) Prevalence of symptoms reported by subjects at the time of initial follow up visit. B) Symptom scores (total number of symptoms reported) with median bars and interquartile range error bars.

Figure 2: Pulmonary function tests and Respiratory Symptom Score. A) Scatter plots show forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and diffusing capacity for carbon monoxide (DLCO) as percentages of predicted values for each subject in the home, non-ICU, and ICU groups. Bars are medians and error bars are interquartile range. Statistical analysis by Kruskal-Wallis test with Benjamini-Hochberg post-hoc test. *P<0.05, **P<0.01, ***P<0.001. B) Scatter plots show the sum of respiratory symptoms (1 point each for dyspnea, cough, and fatigue) vs. forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and diffusing capacity for carbon monoxide (DLCO). Bars are medians and error bars are interquartile range. There were no statistically significant differences between the groups.

Figure 3: Partial least-squares discriminant analysis (PLS-DA). A) The score plot shows each individual subject in the home (blue circles), non-ICU (purple circles), and ICU (red circles) groups. The grey zone in the score plot depicts outliers with 95% confidence. B) The loadings plot depicts associations between clusters and the measured biomarkers.

Figure 4: Biomarkers. A) Plasma levels of LCN2 (lipocalin-2), MMP-7 (matrix metalloproteinase-7), and HGF (hepatocyte growth factor) in individual subjects (black circles) in the home, non-ICU, and ICU groups. Bars are means and error bars are standard deviation. Statistical analysis by one-way ANOVA with Fisher's LSD post-hoc test. *P<0.05, **P<0.01, ***P<0.001. B). Scatter plots for subjects (black circles) of LCN2 (lipocalin-2), MMP-7 (matrix metalloproteinase-7), and HGF (hepatocyte growth factor) on abscissa versus FVC (forced vital

capacity) or DLCO (diffusing capacity) on ordinate. Statistical analysis is simple linear regression. Blue shaded area shows 95% confidence intervals.

REFERENCES

1. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021; 397: 220-232.
2. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in Patients After Acute COVID-19. *JAMA : the journal of the American Medical Association* 2020.
3. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, O'Connor L, Leavy D, O'Brien K, Dowds J, Sugrue JA, Hopkins D, Martin-Loeches I, Ni Cheallaigh C, Nadarajan P, McLaughlin AM, Bourke NM, Bergin C, O'Farrelly C, Bannan C, Conlon N. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. *PloS one* 2020; 15: e0240784.
4. Alwan NA, Attree E, Blair JM, Bogaert D, Bowen MA, Boyle J, Bradman M, Briggs TA, Burns S, Campion D, Cushing K, Delaney B, Dixon C, Dolman GE, Dynan C, Frayling IM, Freeman-Romilly N, Hammond I, Judge J, Jarte L, Lokugamage A, MacDermott N, MacKinnon M, Majithia V, Northridge T, Powell L, Rayner C, Read G, Sahu E, Shand C, Small A, Strachan C, Suett J, Sykes B, Taylor S, Thomas K, Thomson M, Wiltshire A, Woods V. From doctors as patients: a manifesto for tackling persisting symptoms of covid-19. *Bmj* 2020; 370: m3565.
5. Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang C-H, Zhang H, Shallow M, Bahel P, Owusu K, Yamamoto Y, Arora T, Atri DS, Patel A, Gbyli R, Kwan J, Won CH, Dela Cruz C, Price C, Koff J, King BA, Rinder HM, Wilson FP, Hwa J, Halene S, Damsky W, van Dijk D, Lee AI, Chun H. A neutrophil activation signature predicts critical illness and mortality in COVID-19. *medRxiv* 2020: 2020.2009.2001.20183897.
6. Kursa MB, Rudnicki WR. Feature selection with the Boruta package. *J Stat Softw* 2010; 36: 1-13.
7. Sacco V, Rauch B, Gar C, Haschka S, Potzel AL, Kern-Matschilles S, Banning F, Benz I, Meisel M, Seissler J, Lechner A. Overweight/obesity as the potentially most important lifestyle factor associated with signs of pneumonia in COVID-19. *PloS one* 2020; 15: e0237799.
8. Wang J, Xu Y, Zhang X, Wang S, Peng Z, Guo J, Jiang H, Liu J, Xie Y, Wang J, Li X, Liao J, Wan C, Yu L, Hu J, Liu B, Liu Z. Leptin correlates with monocytes activation and severe condition in COVID-19 patients. *J Leukoc Biol* 2021.
9. AbdelMassih AF, Fouda R, Kamel A, Mishriky F, Ismail HA, El Qadi L, Malak L, Mohamed M, Arsanyous M, Hazem M, El-Husseiny M, Ashraf M, Hafez N, AlShehry N, El-Husseiny N, AbdelRaouf N, Shebl N, Hafez N, Youssef N, Afdal P, Hozaien R, Menshawey R, Saeed R, Yasser R, Hesham S, Zakarriah W, Khattab S, Elammary Y, Ye J. Single cell sequencing unraveling genetic basis of severe COVID19 in obesity. *Obes Med* 2020; 20: 100303.
10. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, Meyer JG, Quan Q, Muehlbauer LK, Trujillo EA, He Y, Chopra A, Chieng HC, Tiwari A, Judson MA, Paulson B, Brademan DR, Zhu Y, Serrano LR, Linke V, Drake LA, Adam AP, Schwartz BS, Singer HA, Swanson S, Mosher DF, Stewart R, Coon JJ, Jaitovich A. Large-Scale Multi-omic Analysis of COVID-19 Severity. *Cell Syst* 2020.

11. Li G, Wang J, He X, Zhang L, Ran Q, Xiong A, Wu D, Hu L, Song Q, Zhu D. An integrative analysis identifying transcriptional features and key genes involved in COVID-19. *Epigenomics* 2020; 12: 1969-1981.
12. Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, Zarember KA, Alehashemi S, Oikonomou V, Desai JV, Canna SW, Shakoory B, Dobbs K, Imberti L, Sottini A, Quiros-Roldan E, Castelli F, Rossi C, Brugnoni D, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Castagnoli R, Montagna D, Licari A, Marseglia GL, Gliniewicz EF, Shaw E, Kahle DE, Rastegar AT, Stack M, Myint-Hpu K, Levinson SL, DiNubile MJ, Chertow DW, Burbelo PD, Cohen JI, Calvo KR, Tsang JS, Consortium NC-, Su HC, Gallin JI, Kuhns DB, Goldbach-Mansky R, Lionakis MS, Notarangelo LD. An immune-based biomarker signature is associated with mortality in COVID-19 patients. *JCI Insight* 2021; 6.
13. O'Kane CM, McKeown SW, Perkins GD, Bassford CR, Gao F, Thickett DR, McAuley DF. Salbutamol up-regulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome. *Critical care medicine* 2009; 37: 2242-2249.
14. Davey A, McAuley DF, O'Kane CM. Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. *The European respiratory journal* 2011; 38: 959-970.
15. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, Sciurba F, Dauber J, Selman M, Gochuico BR, Kaminski N. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. *PLoS Med* 2008; 5: e93.
16. Quesnel C, Marchand-Adam S, Fabre A, Marchal-Somme J, Philip I, Lasocki S, Lecon V, Crestani B, Dehoux M. Regulation of hepatocyte growth factor secretion by fibroblasts in patients with acute lung injury. *American journal of physiology Lung cellular and molecular physiology* 2008; 294: L334-343.
17. Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, Wang F, Li G, Li Y, Xing L, Peng L, Yang M, Cao M, Zheng H, Wu W, Zou R, Li D, Xu Z, Wang H, Zhang M, Zhang Z, Gao GF, Jiang C, Liu L, Liu Y. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. *The Journal of allergy and clinical immunology* 2020; 146: 119-127 e114.
18. Ito Y, Correll K, Schiel JA, Finigan JH, Prekeris R, Mason RJ. Lung fibroblasts accelerate wound closure in human alveolar epithelial cells through hepatocyte growth factor/c-Met signaling. *American journal of physiology Lung cellular and molecular physiology* 2014; 307: L94-105.
19. Wang H, Zheng R, Chen Q, Shao J, Yu J, Hu S. Mesenchymal stem cells microvesicles stabilize endothelial barrier function partly mediated by hepatocyte growth factor (HGF). *Stem Cell Res Ther* 2017; 8: 211.
20. Okada M, Sugita K, Inukai T, Goi K, Kagami K, Kawasaki K, Nakazawa S. Hepatocyte growth factor protects small airway epithelial cells from apoptosis induced by tumor necrosis factor-alpha or oxidative stress. *Pediatr Res* 2004; 56: 336-344.
21. Garnier M, Gibelin A, Mailleux AA, Lecon V, Hurtado-Nedelec M, Laschet J, Trebbia G, Neuville M, Tanaka S, Crestani B, Dehoux M, Quesnel C. Macrophage Polarization Favors Epithelial Repair During Acute Respiratory Distress Syndrome. *Critical care medicine* 2018; 46: e692-e701.

22. Kamimoto M, Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor prevents multiple organ injuries in endotoxemic mice through a heme oxygenase-1-dependent mechanism. *Biochemical and biophysical research communications* 2009; 380: 333-337.

Figure 1


Prevalence (%)
80
60
40
20
0
Dyspnea
Cough
Fever
Fatigue
Chest pain
Headache
Anosmia
Dysgeusia
Nausea
Diarrhea
Nasal congestion
Vision loss
Sore throat
Red eyes
Symptom Score
8
6
4
2
0
Home
Non-ICU
ICU

Figure 2


A.
B.
FVC (%predicted)
FEV1 (%predicted)
DLCO (%predicted)
150
100
50
0
***
*
*
**
*
**
Home
non-ICU
ICU
N= 12 27 17
N= 12 27 17
N= 9 24 17
0
1
2
3
Sum of Respiratory Symptoms

Figure 3

A. Score Plot



B. Loadings Plot






A.
B.
FVC
C.
DLCO
LCN2
MMP-7
HGF
LCN2 (pg/ml)
MMP-7 (pg/ml)
HGF (pg/ml)
Home
Non-ICU
ICU
N= 7 5 10
FVC (liters)
DLCO (ml/min/mmHg)
LCN2 (pg/ml)
MMP-7 (pg/ml)
HGF (pg/mL)
HGF (pg/ml)
P=0.0012
P=0.0067
P=0.0025
P=0.0098
P=0.0023
P=0.0261

Supplemental Figure Legends

Supplemental Figure 1: Random-forest feature selection Boruta procedure showing the attributes (biomarkers) in reverse order of importance for explaining variation in forced vital capacity (FVC). Green biomarkers are confirmed and red biomarkers are rejected.

Supplemental Figure 2: Random-forest feature selection Boruta procedure showing the attributes (biomarkers) in reverse order of importance for explaining variation in diffusing capacity for carbon monoxide (DLCO). Green biomarkers are confirmed and red biomarkers are rejected.

Supplemental Figure 3: Top: Scatter plot of leptin levels in individual subjects (black circles) on the abscissa versus forced vital capacity (FVC) on the ordinate. Bottom: Scatter plot of body mass index of individual subjects on the abscissa versus leptin levels on the ordinate. Statistical analysis is by simple linear regression. Blue shaded area shows the 95% confidence intervals.

Supplemental Figure 1



Supplemental Figure 2

Supplemental Figure 3





Supplemental Table: Plasma Biomarkers
ADAMTS13
Adiponectin
Adipsin
Angiopoietin-2 (Ang-2)
BMP-9
C5a
CCL1
CCL11
CCL13
CCL15
CCL17
CCL2
CCL21
CCL22
CCL24
CCL26
CCL27
CCL3
CCL4
CCL5
CCL-7
CCL8
Complement (Comp) Factor 1
CX3CL1
CXCL1
CXCL12
CXCL13
CXCL5
CXCL9
EGF
Endoglin
Endothelin-1
FGF-1
FGF-2
FLT-3L
Follistatin
G-CSF
GM-CSF
HB-EGF
Hepatocyte Growth Factor (HGF)
IFN-a2
IFNy
IL-10
IL-12p40
IL-12p70
IL-13

IL-15
IL-16
IL-17A
IL-17E/IL-25
IL-17F
IL-18
IL-1RA
IL-1α
IL-1β
IL-2
IL-20
IL-21
IL-22
IL-23
IL-27
IL-28A
IL-3
IL-33
IL-4
IL-5
IL-6
IL-7
IL-8
IL-9
IP-10
LCN-2
Leptin
LIF
Mannose Binding Lectin (MBL)
M-CSF
MIF
MMP-1
MMP-10
MMP-12
MMP-13
MMP-2
MMP-3
MMP-7
MMP-8
MMP-9
PAI-1
PDGF-AA
PDGF-AB/BB
PLGF
RETN
SAA
sCD40L
SCF

TGF-α
TIMP-1
TIMP-2
TIMP-3
TIMP-4
TNF-α
TNF-β
TPO
TRAIL
TSLP
VEGF-A
VEGF-C
VEGF-D